Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erika Rimondi

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Frontiers in Bioscience : a Journal and Virtual Library|November 6, 2007
TRAIL and osteoprotegerin: a role in endothelial physiopathology?Federica Corallini, Erika Rimondi, Paola Secchiero
Anatomical Record (Hoboken, N.J. : 2007)|May 17, 2007
Receptor activator of nuclear factor kappa B ligand (RANKL) modulates the expression of genes involved in apoptosis and cell cycle in human osteoclastsErika Rimondi, Marina Zweyer, Enrico Ricci, et al.
Investigational New Drugs|February 5, 2010
Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell linesClaudio Celeghini, Rebecca Voltan, Erika Rimondi, et al.
Investigational New Drugs|November 17, 2012
Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1Erika Rimondi, Paola Secchiero, Elisabetta Melloni, et al.
Journal of Cellular Physiology|October 31, 2009
Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL)Giorgio Zauli, Erika Rimondi, Claudio Celeghini, et al.
Journal of Vascular Surgery. Venous and Lymphatic Disorders|June 19, 2018
Effects of intermittent pneumatic compression treatment on clinical outcomes and biochemical markers in patients at low mobility with lower limb edemaMirko Tessari, Veronica Tisato, Erika Rimondi, et al.
American Journal of Ophthalmology|April 6, 2019
Factors Predictive of Double Anterior Chamber Formation Following Deep Anterior Lamellar KeratoplastyJames Myerscough, Cristina Bovone, Michael Mimouni, et al.
International Journal of Molecular Sciences|May 5, 2021
MitoQ Is Able to Modulate Apoptosis and InflammationElisa Piscianz, Alessandra Tesser, Erika Rimondi, et al.
Blood|June 24, 2004
TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSFGiorgio Zauli, Erika Rimondi, Vanessa Nicolin, et al.
Journal of Experimental Pharmacology|September 10, 2025
Targeting Intestinal Permeability for Graft-versus-Host Disease Treatment: A Therapeutic Perspective with DefibrotideErika Rimondi, Elisabetta Melloni, Paola Secchiero, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Frontiers in Bioscience : a Journal and Virtual Library|November 6, 2007
TRAIL and osteoprotegerin: a role in endothelial physiopathology?Federica Corallini, Erika Rimondi, Paola Secchiero
Anatomical Record (Hoboken, N.J. : 2007)|May 17, 2007
Receptor activator of nuclear factor kappa B ligand (RANKL) modulates the expression of genes involved in apoptosis and cell cycle in human osteoclastsErika Rimondi, Marina Zweyer, Enrico Ricci, et al.
Investigational New Drugs|February 5, 2010
Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell linesClaudio Celeghini, Rebecca Voltan, Erika Rimondi, et al.
Investigational New Drugs|November 17, 2012
Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1Erika Rimondi, Paola Secchiero, Elisabetta Melloni, et al.
Journal of Cellular Physiology|October 31, 2009
Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL)Giorgio Zauli, Erika Rimondi, Claudio Celeghini, et al.
Journal of Vascular Surgery. Venous and Lymphatic Disorders|June 19, 2018
Effects of intermittent pneumatic compression treatment on clinical outcomes and biochemical markers in patients at low mobility with lower limb edemaMirko Tessari, Veronica Tisato, Erika Rimondi, et al.
American Journal of Ophthalmology|April 6, 2019
Factors Predictive of Double Anterior Chamber Formation Following Deep Anterior Lamellar KeratoplastyJames Myerscough, Cristina Bovone, Michael Mimouni, et al.
International Journal of Molecular Sciences|May 5, 2021
MitoQ Is Able to Modulate Apoptosis and InflammationElisa Piscianz, Alessandra Tesser, Erika Rimondi, et al.
Blood|June 24, 2004
TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSFGiorgio Zauli, Erika Rimondi, Vanessa Nicolin, et al.
Journal of Experimental Pharmacology|September 10, 2025
Targeting Intestinal Permeability for Graft-versus-Host Disease Treatment: A Therapeutic Perspective with DefibrotideErika Rimondi, Elisabetta Melloni, Paola Secchiero, et al.
Pageof 7